Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 19:16 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women

ClinicalTrials.gov · NCT06486870 · Registry updated: 2024-07-05

Condition / research focus: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
Sponsor: Cairo University
Countries with listed sites: Egypt
Registry dates and results: Start: 2020-01-01. Completion: 2024-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gonadotropin (drug)
Letrozole (drug)
laparoscopic ovarian drilling (procedure)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

faculty of medicine, Kasr el ainy hospital, Cairo university
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Novel Diagnosis of Ectopic Pregnancy

ClinicalTrials.gov · NCT06486415 · Registry updated: 2024-07-03

Condition / research focus: Ectopic Pregnancy; hCG; Pregnancy of Unknown Location
Sponsor: Acibadem University
Countries with listed sites: No country reported
Registry dates and results: Start: 2024-07-01. Completion: 2025-04-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

serum BHCG testing (diagnostic_test)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility

ClinicalTrials.gov · NCT06481696 · Registry updated: 2024-07-01

Condition / research focus: Unexplained Infertility
Sponsor: Andros Day Surgery Clinic
Countries with listed sites: Italy
Registry dates and results: Start: 2024-06-01. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Resveratrol-based multivitamin supplement (dietary_supplement) — also listed as: Genante
Folic acid (dietary_supplement)
IVF/ICSI (procedure) — also listed as: In vitro fertilization
Follitropin Alfa (drug) — also listed as: Gonal-F
Ganirelix Acetate 0.5 MG/ML [Fyremadel] (drug)
hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously (drug) — also listed as: Gonasi or Decapeptyl

Where the study takes place — 1 listed sites

ANDROS Day Surgery Clinic
Palermo, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)

ClinicalTrials.gov · NCT00696800 · Registry updated: 2024-06-20

Condition / research focus: In Vitro Fertilization
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-06-27. Completion: 2008-01-15 (may be estimated). Results are posted in this registry.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: MK-8962, SCH 900962, Org 36286
RecFSH / Follitropin beta (Days 1 to 7) (biological) — also listed as: Puregon / Follistim AQ Cartridge
Placebo Corifollitropin alfa (drug)
Placebo RecFSH / follitropin beta (drug)
RecFSH / Follitropin beta (Days 8 to hCG) (biological) — also listed as: Puregon / Follistim AQ Cartridge
Ganirelix (drug) — also listed as: Orgalutran/ Ganirelix Acetate Injection
hCG (biological) — also listed as: Pregnyl / urinary hCG
Progesterone (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Cardiometabolic Consequences of the Loss of Ovarian Function

ClinicalTrials.gov · NCT06264882 · Registry updated: 2024-06-20

Condition / research focus: Menopause; Estrogen Deficiency; Aging; Adiposity
Sponsor: University of Colorado, Denver
Countries with listed sites: United States
Registry dates and results: Start: 2024-06-01. Completion: 2028-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Degarelix (drug) — also listed as: GnRH antagonist, Ovarian suppression
Transdermal Estradiol Patch (drug)
Transdermal Placebo Patch (drug)

Where the study takes place — 1 listed sites

University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)

ClinicalTrials.gov · NCT01146418 · Registry updated: 2024-06-20

Condition / research focus: Infertility
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-06-02. Completion: 2014-04-29 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (biological)
recFSH (follitropin beta) (biological) — also listed as: Follistim® AQ Cartridge

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3

ClinicalTrials.gov · NCT06465472 · Registry updated: 2024-06-18

Condition / research focus: Primary Hyperoxaluria Type 1; Primary Hyperoxaluria Type 2; Primary Hyperoxaluria Type 3
Sponsor: Biocodex
Countries with listed sites: No country reported
Registry dates and results: Start: 2024-08. Completion: 2030-08 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Stiripentol Oral Capsule (drug)
Placebo Oral Capsule (drug)
Urine samples collect (biological)
Blood samples collect (biological)
Kidney imaging (other)
Quality of Life questionnaires (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)

ClinicalTrials.gov · NCT00696878 · Registry updated: 2024-06-18

Condition / research focus: In Vitro Fertilization
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-09-26. Completion: 2009-05-15 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: Org 36286, SCH 900962, MK-8962
FSH (biological)
GnRH antagonist (biological)
(rec)hCG (biological)
Progesterone (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)

ClinicalTrials.gov · NCT00702845 · Registry updated: 2024-06-18

Condition / research focus: Infertility
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-12-28. Completion: 2007-11-15 (may be estimated). Results are posted in this registry.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

corifollitropin alfa (Org 36286) (drug) — also listed as: Org 36286
recFSH (follitropin beta) (drug) — also listed as: recFSH (Puregon/Follistim AQ Cartridge)
gonadatropin releasing hormone (GnRH) antagonist (ganirelix) (drug)
human chorion gonadatropin (hCG) (drug)
progesterone (biological)
placebo-recFSH (follitropin alfa) (drug)
placebo-corifollitropin alfa (drug)
open-label recFSH (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Conversion of in Vitro Fertilization Cycles to Intrauterine Inseminations in Patients With a Poor Ovarian Response to Stimulation

ClinicalTrials.gov · NCT03362489 · Registry updated: 2024-06-18

Condition / research focus: Infertility
Sponsor: University Hospital, Angers
Countries with listed sites: France · Guadeloupe
Registry dates and results: Start: 2018-01-10. Completion: 2024-03-14 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IVF / IVF-ICSI (procedure)
IUI (procedure)

Where the study takes place — 32 listed sites

Victor Pauchet Clinic
Amiens, France
Site recruitment: Not reported
UH Angers
Angers, France
Site recruitment: Not reported
UH Besançon
Besançon, France
Site recruitment: Not reported
Jean Verdier Hospital, APHP
Bondy, France
Site recruitment: Not reported
Polyclinique Jean Villar
Bruges, France
Site recruitment: Not reported
UH Caen
Caen, France
Site recruitment: Not reported
Clinique Léonard de Vinci
Chambray-lès-Tours, France
Site recruitment: Not reported
Cholet Hospital
Cholet, France
Site recruitment: Not reported
Antoine Béclère Hospital AP-HP
Clamart, France
Site recruitment: Not reported
Sud Francilien Hospital
Corbeil-Essonnes, France
Site recruitment: Not reported
IHC Créteil
Créteil, France
Site recruitment: Not reported
UH Grenoble
Grenoble, France
Site recruitment: Not reported
Tertre Rouge Clinic
Le Mans, France
Site recruitment: Not reported
UH Lille
Lille, France
Site recruitment: Not reported
Lorient Hospital
Lorient, France
Site recruitment: Not reported
UH La conception AP-HM
Marseille, France
Site recruitment: Not reported
Clinique Jules Verne
Nantes, France
Site recruitment: Not reported
UH Nantes
Nantes, France
Site recruitment: Not reported
Clinique Pierre Cherest
Neuilly-sur-Seine, France
Site recruitment: Not reported
UH Nîmes
Nîmes, France
Site recruitment: Not reported
Hospital of Orléans
Orléans, France
Site recruitment: Not reported
Cochin Hospital, APHP
Paris, France
Site recruitment: Not reported
Poissy Saint Germain en Laye Hospital
Poissy, France
Site recruitment: Not reported
UH Potiers
Potiers, France
Site recruitment: Not reported
Clinique Mutualiste de la Sagesse
Rennes, France
Site recruitment: Not reported
UH Rennes
Rennes, France
Site recruitment: Not reported
UH Rouen
Rouen, France
Site recruitment: Not reported
Polyclinique de L'Atlantique
Saint-Herblain, France
Site recruitment: Not reported
UH Strasbourg
Strasbourg, France
Site recruitment: Not reported
UH Toulouse
Toulouse, France
Site recruitment: Not reported
UHR Tours
Tours, France
Site recruitment: Not reported
UH Pointe-à-Pitre
Pointe-à-Pitre, Guadeloupe/France, Guadeloupe
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)

ClinicalTrials.gov · NCT00697255 · Registry updated: 2024-06-17

Condition / research focus: Ovulation Induction
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2007-05-15. Completion: 2008-05-15 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

corifollitropin alfa (drug) — also listed as: Org 36286, SCH 900962, MK-8962
recombinant Follicle Stimulating Hormone (recFSH) (biological) — also listed as: Puregon®
human Chorion Gonadotropin (hCG) (biological) — also listed as: Pregnyl®
hCG Bolus injection (biological) — also listed as: Pregnyl®

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

HUMAN CHORIONIC GONADOTROPIN (HcG) VS MAGNESIUM SULPHATE (MgSo4) AS A TOCOLYTIC AGENT- A RANDOMIZED CONTROLLED TRIAL

ClinicalTrials.gov · NCT05828966 · Registry updated: 2024-06-07

Condition / research focus: Preterm Labor
Sponsor: Shaheed Zulfiqar Ali Bhutto Medical University
Countries with listed sites: Pakistan
Registry dates and results: Start: 2023-02-15. Completion: 2023-12-20 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (hCG) (drug)
Magnesium sulfate (drug)

Where the study takes place — 1 listed sites

Mother and Child Care Hospital, Shaheed Zulfiqar Ali Bhutto Medical University
Islamabad, Pakistan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)

ClinicalTrials.gov · NCT01709331 · Registry updated: 2024-05-24

Condition / research focus: Hypogonadism; Hypogonadotropic Hypogonadism
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2013-02-11. Completion: 2015-04-08 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: MK-8962
hCG (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)

ClinicalTrials.gov · NCT03019575 · Registry updated: 2024-05-23

Condition / research focus: Hypogonadotropic Hypogonadism
Sponsor: Organon and Co
Countries with listed sites: Brazil · Denmark · Italy · Mexico · Russia · South Africa
Registry dates and results: Start: 2017-02-02. Completion: 2020-05-05 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: MK-8962, Elonva
hCG (drug)

Where the study takes place — 15 listed sites

Centro de Diabetes Curitiba ( Site 0012)
Curitiba, Brazil
Site recruitment: Not reported
Hospital de Clinicas de Porto Alegre ( Site 0014)
Porto Alegre, Brazil
Site recruitment: Not reported
Hosp das Clinicas da Faculdade de Medicina da Univ de Sao Paulo ( Site 0015)
São Paulo, Brazil
Site recruitment: Not reported
Rigshospitalet, University department of Growth and Reproduction ( Site 0051)
Copenhagen, Denmark
Site recruitment: Not reported
AOU Careggi ( Site 0042)
Florence, Italy
Site recruitment: Not reported
Policlinico Umberto I ( Site 0043)
Roma, Italy
Site recruitment: Not reported
IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0044)
Roma, Italy
Site recruitment: Not reported
Instituto Nacional de Pediatria ( Site 0007)
Mexico City, Mexico
Site recruitment: Not reported
Hospital Infantil de Mexico Federico Gomez ( Site 0006)
Mexico City, Mexico
Site recruitment: Not reported
Kazan State Medical University ( Site 0024)
Kazan', Russia
Site recruitment: Not reported
Federal State Budget Institution Endocrinological Research Center ( Site 0021)
Moscow, Russia
Site recruitment: Not reported
City children polyclinic #44 ( Site 0025)
Saint Petersburg, Russia
Site recruitment: Not reported
St.Petersburg State Pediatric Medical University ( Site 0023)
Saint Petersburg, Russia
Site recruitment: Not reported
Republic Children Clinical Hospital ( Site 0022)
Ufa, Russia
Site recruitment: Not reported
Little Company of Mary Hospital ( Site 0017)
Pretoria, South Africa
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial

ClinicalTrials.gov · NCT02418572 · Registry updated: 2024-05-22

Condition / research focus: Infertility; Poor Ovarian Response
Sponsor: Fundacion Dexeus
Countries with listed sites: Belgium · Denmark · Spain · Switzerland
Registry dates and results: Start: 2015-04. Completion: 2024-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Testosterone gel (drug) — also listed as: Androgel 1% 0.55 gr / day
Placebo gel (drug)

Where the study takes place — 10 listed sites

Universitair Ziekenhuis Brussel
Brussels, Belgium
Site recruitment: Not reported
Fertility Clinic Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
The Fertility Clinic, Skive Regional Hospital, Skive, Denmark
Skive, Denmark
Site recruitment: Not reported
Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Not reported
Hospital Universitario 12 de Octubre
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario HM Monteprincipe
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario La Paz
Madrid, Spain
Site recruitment: Not reported
Hospìtal Universitario HM Puerta del Sur
Madrid, Spain
Site recruitment: Not reported
Quiron Madrid Hospital
Madrid, Spain
Site recruitment: Not reported
University Hospital Basel
Basel, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Double Pick up in Poor Prognosis Women

ClinicalTrials.gov · NCT03846544 · Registry updated: 2024-05-21

Condition / research focus: Fertility Disorders
Sponsor: CRG UZ Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2019-10-01. Completion: 2022-10-01 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitoropin alfa (CFA)-double pick up (drug)

Where the study takes place — 1 listed sites

UZ Brussel
Brussels, Jette, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial

ClinicalTrials.gov · NCT04695483 · Registry updated: 2024-05-16

Condition / research focus: Infertility
Sponsor: IRCCS San Raffaele
Countries with listed sites: Italy
Registry dates and results: Start: 2022-02-22. Completion: 2024-05-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug)
Follitropin Beta (drug)

Where the study takes place — 1 listed sites

Enrico Papaleo
Milan, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Ejaculation Abstinence Time and Assisted Reproductive Technology Outcomes

ClinicalTrials.gov · NCT06410417 · Registry updated: 2024-05-13

Condition / research focus: Fertilization in Vitro
Sponsor: The First Hospital of Jilin University
Countries with listed sites: China
Registry dates and results: Start: 2024-05-01. Completion: 2025-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Shorten abstinence time (behavioral)

Where the study takes place — 1 listed sites

the first hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Analysis of the Composition of the Vaginal Microbiota During IVF Treatment and Correlation With Serum Progesterone Level on the Day of Embryo Transfer

ClinicalTrials.gov · NCT04820985 · Registry updated: 2024-04-26

Condition / research focus: IVF
Sponsor: Centre Hospitalier Universitaire de Nīmes
Countries with listed sites: France
Registry dates and results: Start: 2021-05-26. Completion: 2024-04-22 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Vaginal swab (other)
Blood test (other)

Where the study takes place — 1 listed sites

CHU de Nimes
Nîmes, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Malaria Burden in Pregnant Women and the Incidence of Pregnancy in a Cohort of Nulligravida

ClinicalTrials.gov · NCT06162078 · Registry updated: 2024-04-19

Condition / research focus: Maternal Malaria During Pregnancy - Baby Not Yet Delivered
Sponsor: Groupe de Recherche Action en Sante
Countries with listed sites: Burkina Faso
Registry dates and results: Start: 2023-08-25. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

GRAS-Banfora
Banfora, Burkina Faso
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 19:16 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women

ClinicalTrials.gov · NCT06486870 · Registry updated: 2024-07-05

Condition / research focus: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
Sponsor: Cairo University
Countries with listed sites: Egypt
Registry dates and results: Start: 2020-01-01. Completion: 2024-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gonadotropin (drug)
Letrozole (drug)
laparoscopic ovarian drilling (procedure)

Where the study takes place — 1 listed sites

faculty of medicine, Kasr el ainy hospital, Cairo university
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Novel Diagnosis of Ectopic Pregnancy

ClinicalTrials.gov · NCT06486415 · Registry updated: 2024-07-03

Condition / research focus: Ectopic Pregnancy; hCG; Pregnancy of Unknown Location
Sponsor: Acibadem University
Countries with listed sites: No country reported
Registry dates and results: Start: 2024-07-01. Completion: 2025-04-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

serum BHCG testing (diagnostic_test)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility

ClinicalTrials.gov · NCT06481696 · Registry updated: 2024-07-01

Condition / research focus: Unexplained Infertility
Sponsor: Andros Day Surgery Clinic
Countries with listed sites: Italy
Registry dates and results: Start: 2024-06-01. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Resveratrol-based multivitamin supplement (dietary_supplement) — also listed as: Genante
Folic acid (dietary_supplement)
IVF/ICSI (procedure) — also listed as: In vitro fertilization
Follitropin Alfa (drug) — also listed as: Gonal-F
Ganirelix Acetate 0.5 MG/ML [Fyremadel] (drug)
hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously (drug) — also listed as: Gonasi or Decapeptyl

Where the study takes place — 1 listed sites

ANDROS Day Surgery Clinic
Palermo, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)

ClinicalTrials.gov · NCT00696800 · Registry updated: 2024-06-20

Condition / research focus: In Vitro Fertilization
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-06-27. Completion: 2008-01-15 (may be estimated). Results are posted in this registry.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: MK-8962, SCH 900962, Org 36286
RecFSH / Follitropin beta (Days 1 to 7) (biological) — also listed as: Puregon / Follistim AQ Cartridge
Placebo Corifollitropin alfa (drug)
Placebo RecFSH / follitropin beta (drug)
RecFSH / Follitropin beta (Days 8 to hCG) (biological) — also listed as: Puregon / Follistim AQ Cartridge
Ganirelix (drug) — also listed as: Orgalutran/ Ganirelix Acetate Injection
hCG (biological) — also listed as: Pregnyl / urinary hCG
Progesterone (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Cardiometabolic Consequences of the Loss of Ovarian Function

ClinicalTrials.gov · NCT06264882 · Registry updated: 2024-06-20

Condition / research focus: Menopause; Estrogen Deficiency; Aging; Adiposity
Sponsor: University of Colorado, Denver
Countries with listed sites: United States
Registry dates and results: Start: 2024-06-01. Completion: 2028-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Degarelix (drug) — also listed as: GnRH antagonist, Ovarian suppression
Transdermal Estradiol Patch (drug)
Transdermal Placebo Patch (drug)

Where the study takes place — 1 listed sites

University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)

ClinicalTrials.gov · NCT01146418 · Registry updated: 2024-06-20

Condition / research focus: Infertility
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-06-02. Completion: 2014-04-29 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (biological)
recFSH (follitropin beta) (biological) — also listed as: Follistim® AQ Cartridge

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3

ClinicalTrials.gov · NCT06465472 · Registry updated: 2024-06-18

Condition / research focus: Primary Hyperoxaluria Type 1; Primary Hyperoxaluria Type 2; Primary Hyperoxaluria Type 3
Sponsor: Biocodex
Countries with listed sites: No country reported
Registry dates and results: Start: 2024-08. Completion: 2030-08 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Stiripentol Oral Capsule (drug)
Placebo Oral Capsule (drug)
Urine samples collect (biological)
Blood samples collect (biological)
Kidney imaging (other)
Quality of Life questionnaires (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)

ClinicalTrials.gov · NCT00696878 · Registry updated: 2024-06-18

Condition / research focus: In Vitro Fertilization
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-09-26. Completion: 2009-05-15 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: Org 36286, SCH 900962, MK-8962
FSH (biological)
GnRH antagonist (biological)
(rec)hCG (biological)
Progesterone (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)

ClinicalTrials.gov · NCT00702845 · Registry updated: 2024-06-18

Condition / research focus: Infertility
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-12-28. Completion: 2007-11-15 (may be estimated). Results are posted in this registry.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

corifollitropin alfa (Org 36286) (drug) — also listed as: Org 36286
recFSH (follitropin beta) (drug) — also listed as: recFSH (Puregon/Follistim AQ Cartridge)
gonadatropin releasing hormone (GnRH) antagonist (ganirelix) (drug)
human chorion gonadatropin (hCG) (drug)
progesterone (biological)
placebo-recFSH (follitropin alfa) (drug)
placebo-corifollitropin alfa (drug)
open-label recFSH (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Conversion of in Vitro Fertilization Cycles to Intrauterine Inseminations in Patients With a Poor Ovarian Response to Stimulation

ClinicalTrials.gov · NCT03362489 · Registry updated: 2024-06-18

Condition / research focus: Infertility
Sponsor: University Hospital, Angers
Countries with listed sites: France · Guadeloupe
Registry dates and results: Start: 2018-01-10. Completion: 2024-03-14 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IVF / IVF-ICSI (procedure)
IUI (procedure)

Where the study takes place — 32 listed sites

Victor Pauchet Clinic
Amiens, France
Site recruitment: Not reported
UH Angers
Angers, France
Site recruitment: Not reported
UH Besançon
Besançon, France
Site recruitment: Not reported
Jean Verdier Hospital, APHP
Bondy, France
Site recruitment: Not reported
Polyclinique Jean Villar
Bruges, France
Site recruitment: Not reported
UH Caen
Caen, France
Site recruitment: Not reported
Clinique Léonard de Vinci
Chambray-lès-Tours, France
Site recruitment: Not reported
Cholet Hospital
Cholet, France
Site recruitment: Not reported
Antoine Béclère Hospital AP-HP
Clamart, France
Site recruitment: Not reported
Sud Francilien Hospital
Corbeil-Essonnes, France
Site recruitment: Not reported
IHC Créteil
Créteil, France
Site recruitment: Not reported
UH Grenoble
Grenoble, France
Site recruitment: Not reported
Tertre Rouge Clinic
Le Mans, France
Site recruitment: Not reported
UH Lille
Lille, France
Site recruitment: Not reported
Lorient Hospital
Lorient, France
Site recruitment: Not reported
UH La conception AP-HM
Marseille, France
Site recruitment: Not reported
Clinique Jules Verne
Nantes, France
Site recruitment: Not reported
UH Nantes
Nantes, France
Site recruitment: Not reported
Clinique Pierre Cherest
Neuilly-sur-Seine, France
Site recruitment: Not reported
UH Nîmes
Nîmes, France
Site recruitment: Not reported
Hospital of Orléans
Orléans, France
Site recruitment: Not reported
Cochin Hospital, APHP
Paris, France
Site recruitment: Not reported
Poissy Saint Germain en Laye Hospital
Poissy, France
Site recruitment: Not reported
UH Potiers
Potiers, France
Site recruitment: Not reported
Clinique Mutualiste de la Sagesse
Rennes, France
Site recruitment: Not reported
UH Rennes
Rennes, France
Site recruitment: Not reported
UH Rouen
Rouen, France
Site recruitment: Not reported
Polyclinique de L'Atlantique
Saint-Herblain, France
Site recruitment: Not reported
UH Strasbourg
Strasbourg, France
Site recruitment: Not reported
UH Toulouse
Toulouse, France
Site recruitment: Not reported
UHR Tours
Tours, France
Site recruitment: Not reported
UH Pointe-à-Pitre
Pointe-à-Pitre, Guadeloupe/France, Guadeloupe
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)

ClinicalTrials.gov · NCT00697255 · Registry updated: 2024-06-17

Condition / research focus: Ovulation Induction
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2007-05-15. Completion: 2008-05-15 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

corifollitropin alfa (drug) — also listed as: Org 36286, SCH 900962, MK-8962
recombinant Follicle Stimulating Hormone (recFSH) (biological) — also listed as: Puregon®
human Chorion Gonadotropin (hCG) (biological) — also listed as: Pregnyl®
hCG Bolus injection (biological) — also listed as: Pregnyl®

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

HUMAN CHORIONIC GONADOTROPIN (HcG) VS MAGNESIUM SULPHATE (MgSo4) AS A TOCOLYTIC AGENT- A RANDOMIZED CONTROLLED TRIAL

ClinicalTrials.gov · NCT05828966 · Registry updated: 2024-06-07

Condition / research focus: Preterm Labor
Sponsor: Shaheed Zulfiqar Ali Bhutto Medical University
Countries with listed sites: Pakistan
Registry dates and results: Start: 2023-02-15. Completion: 2023-12-20 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (hCG) (drug)
Magnesium sulfate (drug)

Where the study takes place — 1 listed sites

Mother and Child Care Hospital, Shaheed Zulfiqar Ali Bhutto Medical University
Islamabad, Pakistan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)

ClinicalTrials.gov · NCT01709331 · Registry updated: 2024-05-24

Condition / research focus: Hypogonadism; Hypogonadotropic Hypogonadism
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2013-02-11. Completion: 2015-04-08 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: MK-8962
hCG (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)

ClinicalTrials.gov · NCT03019575 · Registry updated: 2024-05-23

Condition / research focus: Hypogonadotropic Hypogonadism
Sponsor: Organon and Co
Countries with listed sites: Brazil · Denmark · Italy · Mexico · Russia · South Africa
Registry dates and results: Start: 2017-02-02. Completion: 2020-05-05 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: MK-8962, Elonva
hCG (drug)

Where the study takes place — 15 listed sites

Centro de Diabetes Curitiba ( Site 0012)
Curitiba, Brazil
Site recruitment: Not reported
Hospital de Clinicas de Porto Alegre ( Site 0014)
Porto Alegre, Brazil
Site recruitment: Not reported
Hosp das Clinicas da Faculdade de Medicina da Univ de Sao Paulo ( Site 0015)
São Paulo, Brazil
Site recruitment: Not reported
Rigshospitalet, University department of Growth and Reproduction ( Site 0051)
Copenhagen, Denmark
Site recruitment: Not reported
AOU Careggi ( Site 0042)
Florence, Italy
Site recruitment: Not reported
Policlinico Umberto I ( Site 0043)
Roma, Italy
Site recruitment: Not reported
IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0044)
Roma, Italy
Site recruitment: Not reported
Instituto Nacional de Pediatria ( Site 0007)
Mexico City, Mexico
Site recruitment: Not reported
Hospital Infantil de Mexico Federico Gomez ( Site 0006)
Mexico City, Mexico
Site recruitment: Not reported
Kazan State Medical University ( Site 0024)
Kazan', Russia
Site recruitment: Not reported
Federal State Budget Institution Endocrinological Research Center ( Site 0021)
Moscow, Russia
Site recruitment: Not reported
City children polyclinic #44 ( Site 0025)
Saint Petersburg, Russia
Site recruitment: Not reported
St.Petersburg State Pediatric Medical University ( Site 0023)
Saint Petersburg, Russia
Site recruitment: Not reported
Republic Children Clinical Hospital ( Site 0022)
Ufa, Russia
Site recruitment: Not reported
Little Company of Mary Hospital ( Site 0017)
Pretoria, South Africa
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial

ClinicalTrials.gov · NCT02418572 · Registry updated: 2024-05-22

Condition / research focus: Infertility; Poor Ovarian Response
Sponsor: Fundacion Dexeus
Countries with listed sites: Belgium · Denmark · Spain · Switzerland
Registry dates and results: Start: 2015-04. Completion: 2024-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Testosterone gel (drug) — also listed as: Androgel 1% 0.55 gr / day
Placebo gel (drug)

Where the study takes place — 10 listed sites

Universitair Ziekenhuis Brussel
Brussels, Belgium
Site recruitment: Not reported
Fertility Clinic Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
The Fertility Clinic, Skive Regional Hospital, Skive, Denmark
Skive, Denmark
Site recruitment: Not reported
Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Not reported
Hospital Universitario 12 de Octubre
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario HM Monteprincipe
Madrid, Spain
Site recruitment: Not reported
Hospital Universitario La Paz
Madrid, Spain
Site recruitment: Not reported
Hospìtal Universitario HM Puerta del Sur
Madrid, Spain
Site recruitment: Not reported
Quiron Madrid Hospital
Madrid, Spain
Site recruitment: Not reported
University Hospital Basel
Basel, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Double Pick up in Poor Prognosis Women

ClinicalTrials.gov · NCT03846544 · Registry updated: 2024-05-21

Condition / research focus: Fertility Disorders
Sponsor: CRG UZ Brussel
Countries with listed sites: Belgium
Registry dates and results: Start: 2019-10-01. Completion: 2022-10-01 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitoropin alfa (CFA)-double pick up (drug)

Where the study takes place — 1 listed sites

UZ Brussel
Brussels, Jette, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial

ClinicalTrials.gov · NCT04695483 · Registry updated: 2024-05-16

Condition / research focus: Infertility
Sponsor: IRCCS San Raffaele
Countries with listed sites: Italy
Registry dates and results: Start: 2022-02-22. Completion: 2024-05-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug)
Follitropin Beta (drug)

Where the study takes place — 1 listed sites

Enrico Papaleo
Milan, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Ejaculation Abstinence Time and Assisted Reproductive Technology Outcomes

ClinicalTrials.gov · NCT06410417 · Registry updated: 2024-05-13

Condition / research focus: Fertilization in Vitro
Sponsor: The First Hospital of Jilin University
Countries with listed sites: China
Registry dates and results: Start: 2024-05-01. Completion: 2025-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Shorten abstinence time (behavioral)

Where the study takes place — 1 listed sites

the first hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Analysis of the Composition of the Vaginal Microbiota During IVF Treatment and Correlation With Serum Progesterone Level on the Day of Embryo Transfer

ClinicalTrials.gov · NCT04820985 · Registry updated: 2024-04-26

Condition / research focus: IVF
Sponsor: Centre Hospitalier Universitaire de Nīmes
Countries with listed sites: France
Registry dates and results: Start: 2021-05-26. Completion: 2024-04-22 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Vaginal swab (other)
Blood test (other)

Where the study takes place — 1 listed sites

CHU de Nimes
Nîmes, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Malaria Burden in Pregnant Women and the Incidence of Pregnancy in a Cohort of Nulligravida

ClinicalTrials.gov · NCT06162078 · Registry updated: 2024-04-19

Condition / research focus: Maternal Malaria During Pregnancy - Baby Not Yet Delivered
Sponsor: Groupe de Recherche Action en Sante
Countries with listed sites: Burkina Faso
Registry dates and results: Start: 2023-08-25. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

GRAS-Banfora
Banfora, Burkina Faso
Site recruitment: Recruiting

Original record, eligibility, contacts and results →